238 related articles for article (PubMed ID: 27044576)
1. Behaviour-change intervention in a multicentre, randomised, placebo-controlled COPD study: methodological considerations and implementation.
Bourbeau J; Lavoie KL; Sedeno M; De Sousa D; Erzen D; Hamilton A; Maltais F; Troosters T; Leidy N
BMJ Open; 2016 Apr; 6(4):e010109. PubMed ID: 27044576
[TBL] [Abstract][Full Text] [Related]
2. Enhancing exercise tolerance and physical activity in COPD with combined pharmacological and non-pharmacological interventions: PHYSACTO randomised, placebo-controlled study design.
Troosters T; Bourbeau J; Maltais F; Leidy N; Erzen D; De Sousa D; Korducki L; Hamilton A
BMJ Open; 2016 Apr; 6(4):e010106. PubMed ID: 27075841
[TBL] [Abstract][Full Text] [Related]
3. Effect of Bronchodilation, Exercise Training, and Behavior Modification on Symptoms and Physical Activity in Chronic Obstructive Pulmonary Disease.
Troosters T; Maltais F; Leidy N; Lavoie KL; Sedeno M; Janssens W; Garcia-Aymerich J; Erzen D; De Sousa D; Korducki L; Hamilton A; Bourbeau J
Am J Respir Crit Care Med; 2018 Oct; 198(8):1021-1032. PubMed ID: 29664681
[TBL] [Abstract][Full Text] [Related]
4. Study Design of VESUTO
Ichinose M; Minakata Y; Motegi T; Ueki J; Seki T; Anzai T; Takizawa A; Grönke L; Hirata K
Adv Ther; 2017 Jul; 34(7):1622-1635. PubMed ID: 28537001
[TBL] [Abstract][Full Text] [Related]
5. Randomized, Double-Blind, Dose-Finding Study for Tiotropium when Added to Olodaterol, Administered via the Respimat® Inhaler in Patients with Chronic Obstructive Pulmonary Disease.
Aalbers R; Maleki-Yazdi MR; Hamilton A; Waitere-Wijker S; Zhao Y; Amatto VC; Schmidt O; Bjermer L
Adv Ther; 2015 Sep; 32(9):809-22. PubMed ID: 26404912
[TBL] [Abstract][Full Text] [Related]
6. Effect of 12 weeks of once-daily tiotropium/olodaterol on exercise endurance during constant work-rate cycling and endurance shuttle walking in chronic obstructive pulmonary disease.
Maltais F; O'Donnell D; Gáldiz Iturri JB; Kirsten AM; Singh D; Hamilton A; Tetzlaff K; Zhao Y; Casaburi R
Ther Adv Respir Dis; 2018; 12():1753465818755091. PubMed ID: 29439648
[TBL] [Abstract][Full Text] [Related]
7. Effects of combined tiotropium/olodaterol on inspiratory capacity and exercise endurance in COPD.
O'Donnell DE; Casaburi R; Frith P; Kirsten A; De Sousa D; Hamilton A; Xue W; Maltais F
Eur Respir J; 2017 Apr; 49(4):. PubMed ID: 28424359
[TBL] [Abstract][Full Text] [Related]
8. The lung function profile of once-daily tiotropium and olodaterol via Respimat(®) is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler(®) (ENERGITO(®) study).
Beeh KM; Derom E; Echave-Sustaeta J; Grönke L; Hamilton A; Zhai D; Bjermer L
Int J Chron Obstruct Pulmon Dis; 2016; 11():193-205. PubMed ID: 26893551
[TBL] [Abstract][Full Text] [Related]
9. Assessment of physical functioning and handling of tiotropium/olodaterol Respimat
Steinmetz KO; Abenhardt B; Pabst S; Hänsel M; Kondla A; Bayer V; Buhl R
Int J Chron Obstruct Pulmon Dis; 2019; 14():1441-1453. PubMed ID: 31308649
[TBL] [Abstract][Full Text] [Related]
10. Impact of tiotropium + olodaterol on physical functioning in COPD: results of an open-label observational study.
Sauer R; Hänsel M; Buhl R; Rubin RA; Frey M; Glaab T
Int J Chron Obstruct Pulmon Dis; 2016; 11():891-8. PubMed ID: 27217742
[TBL] [Abstract][Full Text] [Related]
11. Effect of tiotropium and olodaterol on symptoms and patient-reported outcomes in patients with COPD: results from four randomised, double-blind studies.
Ferguson GT; Karpel J; Bennett N; Clerisme-Beaty E; Grönke L; Voß F; Buhl R
NPJ Prim Care Respir Med; 2017 Feb; 27(1):7. PubMed ID: 28154373
[TBL] [Abstract][Full Text] [Related]
12. The once-daily fixed-dose combination of olodaterol and tiotropium in the management of COPD: current evidence and future prospects.
Derom E; Brusselle GG; Joos GF
Ther Adv Respir Dis; 2019; 13():1753466619843426. PubMed ID: 31002020
[TBL] [Abstract][Full Text] [Related]
13. Development of an enhanced health-economic model and cost-effectiveness analysis of tiotropium + olodaterol Respimat® fixed-dose combination for chronic obstructive pulmonary disease patients in Italy.
Selya-Hammer C; Gonzalez-Rojas Guix N; Baldwin M; Ternouth A; Miravitlles M; Rutten-van Mölken M; Goosens LM; Buyukkaramikli N; Acciai V
Ther Adv Respir Dis; 2016 Oct; 10(5):391-401. PubMed ID: 27405723
[TBL] [Abstract][Full Text] [Related]
14. Tiotropium and exercise training in COPD patients: effects on dyspnea and exercise tolerance.
Ambrosino N; Foglio K; Balzano G; Paggiaro PL; Lessi P; Kesten S;
Int J Chron Obstruct Pulmon Dis; 2008; 3(4):771-80. PubMed ID: 19281092
[TBL] [Abstract][Full Text] [Related]
15. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4).
Buhl R; Maltais F; Abrahams R; Bjermer L; Derom E; Ferguson G; Fležar M; Hébert J; McGarvey L; Pizzichini E; Reid J; Veale A; Grönke L; Hamilton A; Korducki L; Tetzlaff K; Waitere-Wijker S; Watz H; Bateman E
Eur Respir J; 2015 Apr; 45(4):969-79. PubMed ID: 25573406
[TBL] [Abstract][Full Text] [Related]
16. Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial.
Calverley PMA; Anzueto AR; Carter K; Grönke L; Hallmann C; Jenkins C; Wedzicha J; Rabe KF
Lancet Respir Med; 2018 May; 6(5):337-344. PubMed ID: 29605624
[TBL] [Abstract][Full Text] [Related]
17. The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease.
Beeh KM; Westerman J; Kirsten AM; Hébert J; Grönke L; Hamilton A; Tetzlaff K; Derom E
Pulm Pharmacol Ther; 2015 Jun; 32():53-9. PubMed ID: 25956072
[TBL] [Abstract][Full Text] [Related]
18. Dual bronchodilation with tiotropium/olodaterol further reduces activity-related breathlessness
Maltais F; Aumann JL; Kirsten AM; Nadreau É; Macesic H; Jin X; Hamilton A; O'Donnell DE
Eur Respir J; 2019 Mar; 53(3):. PubMed ID: 30655277
[TBL] [Abstract][Full Text] [Related]
19. [The efficacy and safety of tiotropium/olodaterol fixed-dose combination in Chinese patients with chronic obstructive pulmonary disease: a pooled subgroup analysis of TONADO 1+2].
Bai CX; Tang Y; Xin JB; Li YL; Li ZK; Kang J; Huang JA; Xiao W; Wen ZG; Fu XH; He B; Liu CT; Chen P
Zhonghua Jie He He Hu Xi Za Zhi; 2019 Nov; 42(11):838-844. PubMed ID: 31694094
[No Abstract] [Full Text] [Related]
20. Effects of Tiotropium/Olodaterol on Activity-Related Breathlessness, Exercise Endurance and Physical Activity in Patients with COPD: Narrative Review with Meta-/Pooled Analyses.
Maltais F; de la Hoz A; Casaburi R; O'Donnell D
Adv Ther; 2021 Feb; 38(2):835-853. PubMed ID: 33306188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
